MX2017010795A - Proteínas biológicas condicionalmente activas. - Google Patents
Proteínas biológicas condicionalmente activas.Info
- Publication number
- MX2017010795A MX2017010795A MX2017010795A MX2017010795A MX2017010795A MX 2017010795 A MX2017010795 A MX 2017010795A MX 2017010795 A MX2017010795 A MX 2017010795A MX 2017010795 A MX2017010795 A MX 2017010795A MX 2017010795 A MX2017010795 A MX 2017010795A
- Authority
- MX
- Mexico
- Prior art keywords
- proteins
- conditionally active
- methods
- active biological
- biological proteins
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 7
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 238000000034 method Methods 0.000 abstract 4
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Ecology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos para generar proteínas biológicas condicionalmente activas, en particular proteínas terapéuticas o de diagnóstico, que son más activas en una condición aberrante que en una condición fisiológica normal. Los métodos incluyen métodos de descubrimiento que utilizan bibliotecas de proteínas y ensayos que emplean concentraciones fisiológicas de componentes de fluidos corporales. Las proteínas biológicas condicionalmente activas se pueden evolucionar más, conjugarse a otras moléculas, enmascararse, reducir su actividad al unirlas a una fracción escindible. También se divulgan los criterios para seleccionar las proteínas de inicio para los métodos de descubrimiento, así como los formatos de las proteínas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562120312P | 2015-02-24 | 2015-02-24 | |
US201562249907P | 2015-11-02 | 2015-11-02 | |
PCT/US2016/019242 WO2016138071A1 (en) | 2015-02-24 | 2016-02-24 | Conditionally active biological proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017010795A true MX2017010795A (es) | 2018-04-11 |
Family
ID=56789902
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010795A MX2017010795A (es) | 2015-02-24 | 2016-02-24 | Proteínas biológicas condicionalmente activas. |
MX2020011052A MX2020011052A (es) | 2015-02-24 | 2017-08-22 | Proteinas biologicas condicionalmente activas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011052A MX2020011052A (es) | 2015-02-24 | 2017-08-22 | Proteinas biologicas condicionalmente activas. |
Country Status (11)
Country | Link |
---|---|
US (3) | US10563194B2 (es) |
EP (1) | EP3262217A4 (es) |
JP (3) | JP7025214B2 (es) |
KR (3) | KR20230109773A (es) |
CN (1) | CN107580603A (es) |
AU (3) | AU2016222830B2 (es) |
CA (2) | CA3225013A1 (es) |
MX (2) | MX2017010795A (es) |
RU (1) | RU2733658C2 (es) |
SG (2) | SG10202108814VA (es) |
WO (1) | WO2016138071A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3083689T (pt) | 2013-12-17 | 2020-08-27 | Genentech Inc | Anticorpos anti-cd3 e métodos de utilização |
CN106459960A (zh) * | 2014-05-13 | 2017-02-22 | 生物蛋白有限公司 | 条件活性生物蛋白 |
KR20230172625A (ko) | 2014-08-28 | 2023-12-22 | 바이오아트라, 인코퍼레이티드 | 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체 |
KR20230044567A (ko) * | 2016-05-13 | 2023-04-04 | 바이오아트라, 인코퍼레이티드 | 항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도 |
KR102585956B1 (ko) * | 2016-08-31 | 2023-10-05 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 폴리펩티드 및 이를 제조하는 방법 |
KR20240029119A (ko) | 2016-11-15 | 2024-03-05 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약 |
MX2019007981A (es) | 2017-01-03 | 2019-10-15 | Bioatla Llc | Terapeutica de proteinas para el tratamiento de celulas senescentes. |
WO2018189611A1 (en) * | 2017-04-12 | 2018-10-18 | Pfizer Inc. | Antibodies having conditional affinity and methods of use thereof |
CN112292396A (zh) * | 2018-06-05 | 2021-01-29 | 生物蛋白有限公司 | 抗il-22抗体,抗体片段,其免疫结合物及其用途 |
SG11202012405WA (en) * | 2018-06-14 | 2021-01-28 | Bioatla Inc | Multi-specific antibody constructs |
CN111505288B (zh) * | 2020-05-15 | 2022-03-01 | 重庆医科大学 | 一种新的抑郁症生物标志物及其应用 |
CN114259460B (zh) * | 2020-09-16 | 2024-03-15 | 苏州大学 | 基于免疫佐剂的水凝胶组合物及其应用 |
AU2022371170A1 (en) * | 2021-10-19 | 2024-05-02 | Bioatla, Inc. | Conditionally active proteins for neurodegenerative diseases |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
JPH05236997A (ja) | 1992-02-28 | 1993-09-17 | Hitachi Ltd | ポリヌクレオチド捕捉用チップ |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US6468742B2 (en) | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
JP2000503527A (ja) * | 1995-11-28 | 2000-03-28 | ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン | 条件付き複製ウイルスベクターおよびその用途 |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
WO1997034911A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
WO1997046313A1 (en) | 1996-06-07 | 1997-12-11 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
US6826296B2 (en) | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
CA2300940A1 (en) | 1997-08-15 | 1999-02-25 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
DK1012564T3 (da) | 1997-09-11 | 2003-07-21 | Bioventures Inc | Fremgangsmåde til at fremstille højtæthedsarrays |
US6465178B2 (en) | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
AU753157B2 (en) | 1997-11-03 | 2002-10-10 | Georgetown University Medical Center | VEGI, an inhibitor of angiogenesis and tumor growth |
US6537749B2 (en) | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US20090130718A1 (en) | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
US6221653B1 (en) | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
US6653151B2 (en) | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
US20010008765A1 (en) | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
CN100390288C (zh) | 2000-04-11 | 2008-05-28 | 杰南技术公司 | 多价抗体及其应用 |
ES2335391T3 (es) * | 2001-04-27 | 2010-03-26 | Vivoxid Oy | Procedimiento para mejorar la fijacion del tejido blando e implantes utilizando dicho procedimiento. |
CA2488836A1 (en) | 2002-06-12 | 2003-12-24 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
US7919089B2 (en) | 2003-05-31 | 2011-04-05 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for EpCAM |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
EP1716178B1 (en) | 2004-02-16 | 2010-08-11 | Micromet AG | Less immunogenic binding molecules |
US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
RU2367667C2 (ru) | 2004-08-19 | 2009-09-20 | Дженентек, Инк. | Полипептидные варианты с измененной эффекторной функцией |
ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
CA2633594C (en) | 2005-12-16 | 2021-10-26 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
AU2006327175A1 (en) | 2005-12-21 | 2007-06-28 | Medimmune, Llc | Epha2 bite molecules and uses thereof |
RU2426743C2 (ru) | 2005-12-21 | 2011-08-20 | Микромет Аг | Фармацевтические композиции с устойчивостью к растворимому сеа |
CA2682626A1 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
US9260522B2 (en) | 2008-10-01 | 2016-02-16 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
AU2009313040B2 (en) | 2008-11-07 | 2015-07-09 | Amgen Research (Munich) Gmbh | Treatment of acute lymphoblastic leukemia |
CN102341502B (zh) | 2008-12-31 | 2015-07-01 | 代谢探索者公司 | 用于制备二醇的方法 |
RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
KR101979188B1 (ko) | 2009-03-09 | 2019-05-16 | 바이오아트라, 엘엘씨 | 미락 단백질 |
CA3042565A1 (en) | 2009-04-30 | 2010-11-04 | Genomatica, Inc. | Microorganism expressing exogenous crotonase for producing 1,3-butanediol |
US8449773B2 (en) | 2009-07-06 | 2013-05-28 | Brigham Young University | Method for pretreatment of cellulosic and lignocellulosic materials for conversion into bioenergy |
SG177687A1 (en) | 2009-07-17 | 2012-02-28 | Bioatla Llc | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
CA2810668A1 (en) | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
AU2012273177A1 (en) | 2011-06-22 | 2013-05-02 | Genomatica, Inc. | Microorganisms for producing 1,3-butanediol and methods related thereto |
MX366269B (es) * | 2011-09-30 | 2019-07-04 | Chugai Pharmaceutical Co Ltd | Biblioteca de moleculas de union dependientes de la concentracion ionica. |
CA2866612C (en) * | 2012-03-08 | 2018-01-16 | Halozyme, Inc. | Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof |
US20140206596A1 (en) | 2013-01-18 | 2014-07-24 | University Of Southern California | Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions |
-
2016
- 2016-02-24 SG SG10202108814VA patent/SG10202108814VA/en unknown
- 2016-02-24 MX MX2017010795A patent/MX2017010795A/es active IP Right Grant
- 2016-02-24 KR KR1020237022948A patent/KR20230109773A/ko not_active Application Discontinuation
- 2016-02-24 EP EP16756238.8A patent/EP3262217A4/en active Pending
- 2016-02-24 US US15/546,883 patent/US10563194B2/en active Active
- 2016-02-24 RU RU2017127972A patent/RU2733658C2/ru active
- 2016-02-24 KR KR1020177023331A patent/KR102286801B1/ko active IP Right Grant
- 2016-02-24 WO PCT/US2016/019242 patent/WO2016138071A1/en active Application Filing
- 2016-02-24 CA CA3225013A patent/CA3225013A1/en active Pending
- 2016-02-24 CA CA2977687A patent/CA2977687C/en active Active
- 2016-02-24 AU AU2016222830A patent/AU2016222830B2/en active Active
- 2016-02-24 KR KR1020217024058A patent/KR20210096326A/ko not_active IP Right Cessation
- 2016-02-24 SG SG11201705988UA patent/SG11201705988UA/en unknown
- 2016-02-24 CN CN201680012058.5A patent/CN107580603A/zh active Pending
- 2016-02-24 JP JP2017562970A patent/JP7025214B2/ja active Active
-
2017
- 2017-08-22 MX MX2020011052A patent/MX2020011052A/es unknown
-
2020
- 2020-01-03 US US16/733,358 patent/US11254932B2/en active Active
-
2021
- 2021-05-28 AU AU2021203506A patent/AU2021203506B2/en active Active
- 2021-11-12 JP JP2021184506A patent/JP2022031720A/ja active Pending
-
2022
- 2022-01-11 US US17/573,389 patent/US20220127595A1/en active Pending
-
2023
- 2023-09-26 JP JP2023163210A patent/JP2023182651A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203877A patent/AU2024203877A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200199578A1 (en) | 2020-06-25 |
AU2024203877A1 (en) | 2024-06-27 |
US11254932B2 (en) | 2022-02-22 |
AU2021203506B2 (en) | 2024-06-27 |
JP2022031720A (ja) | 2022-02-22 |
KR20170117089A (ko) | 2017-10-20 |
JP2018513206A (ja) | 2018-05-24 |
US10563194B2 (en) | 2020-02-18 |
CA2977687A1 (en) | 2016-09-01 |
SG11201705988UA (en) | 2017-08-30 |
AU2016222830B2 (en) | 2021-02-25 |
RU2017127972A3 (es) | 2019-08-09 |
KR102286801B1 (ko) | 2021-08-09 |
JP7025214B2 (ja) | 2022-02-24 |
CA3225013A1 (en) | 2016-09-01 |
CN107580603A (zh) | 2018-01-12 |
EP3262217A4 (en) | 2018-07-18 |
US20190024078A1 (en) | 2019-01-24 |
RU2733658C2 (ru) | 2020-10-06 |
AU2016222830A1 (en) | 2017-08-10 |
WO2016138071A1 (en) | 2016-09-01 |
US20220127595A1 (en) | 2022-04-28 |
RU2017127972A (ru) | 2019-03-25 |
KR20230109773A (ko) | 2023-07-20 |
SG10202108814VA (en) | 2021-09-29 |
KR20210096326A (ko) | 2021-08-04 |
CA2977687C (en) | 2024-02-13 |
AU2021203506A1 (en) | 2021-06-17 |
MX2020011052A (es) | 2020-11-06 |
EP3262217A1 (en) | 2018-01-03 |
JP2023182651A (ja) | 2023-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011052A (es) | Proteinas biologicas condicionalmente activas. | |
MX2019007981A (es) | Terapeutica de proteinas para el tratamiento de celulas senescentes. | |
MX353482B (es) | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. | |
MX2018004852A (es) | Proteinas mirac. | |
WO2012040459A3 (en) | Beta-catenin targeting peptides and uses thereof | |
MX361218B (es) | Análogos de spliceostatina. | |
MY189483A (en) | Purinone derivative | |
EA200800564A1 (ru) | Производные ксантина как селективные агонисты нм74а | |
JO3357B1 (ar) | مركبات إيميدازوبيروليدينون | |
UA95244C2 (ru) | Соединения и способ модулирования активности киназ, и показания для их применения | |
MX349748B (es) | Cánula escalonada. | |
AU2012205878A8 (en) | miRNA for treating diseases and conditions associated with neo-angiogenesis | |
AU2011274619A8 (en) | miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway | |
MY200925A (en) | Peptide Amide Compound and Preparation Method and Medical use Thereof | |
MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
MX2009007436A (es) | Derivados espirociclicos de acido tetronico. | |
WO2014066915A3 (en) | Methods and compositions to produce ss-rnai activity with enhanced potency | |
UY29046A1 (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su uso en terapia | |
MA32723B1 (fr) | Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments | |
AU2011208681A8 (en) | Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease | |
GEP20156332B (en) | Pyrazoles as crth2 antagonists | |
WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
BR112013008420A2 (pt) | composto, medicamento, e, uso do composito | |
EA201000864A1 (ru) | Фенилоксетанильные производные | |
AU2009235634A8 (en) | Substituted sulfonamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |